Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GVAX: Phase I/II

Interim data from 14 patients who received at least one GVAX vaccination in a U.S.

Read the full 153 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE